This application seeks support for the activities of the National Clinical Trials Network (NCTN) as a Network Lead Academic Participating Site at the University of Wisconsin Carbone Cancer Center (UWCCC). For over 40 years, the UWCCC has maintained exemplary main institution accrual and strong affiliate participation while providing high quality data and key scientific leadership. The basic, translational, and clinical research programs of the UWCCC are designed to reduce the cancer burden on the population by improving prevention, early detection, and treatment of cancer. The UWCCC's commitment to cancer care and research has never been stronger and since 2002, an overall tripling of UWCCC clinical and research space has been implemented. The UWCCC faculty views the NCI cooperative groups as essential components in the war on cancer. Translation of scientific discovery to human populations and to individual patients requires an ability to conduct large scale clinical trials in a timely fashion. The NCTN provides this vital forum and the UWCCC remains highly committed and dedicated to this mutually beneficial partnership.
NCTN clinical trials are a vitally important cancer treatment option for the citizens of Wisconsin. Group trials represent a proven system for improving outcomes for patients affected by cancer and the University of Wisconsin remains enthusiastic participants in the cooperative group system.
|Laport, Ginna G; Wu, Juan; Logan, Brent et al. (2016) Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Networ Biol Blood Marrow Transplant 22:1440-8|
|Press, Oliver W; Li, Hongli; SchÃ¶der, Heiko et al. (2016) US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816. J Clin Oncol 34:2020-7|
|Boughey, Judy C; Ballman, Karla V; Le-Petross, Huong T et al. (2016) Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance) Ann Surg 263:802-7|
|Tevaarwerk, Amye J; Lee, Ju-Whei; Terhaar, Abigail et al. (2016) Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOG-ACRIN's Symptom Outcomes and Practice Patterns study. Cancer 122:438-46|
|Kenkre, Vaishalee P; Hong, Fangxin; Cerhan, James R et al. (2016) Fc Gamma Receptor 3A and 2A Polymorphisms Do Not Predict Response to Rituximab in Follicular Lymphoma. Clin Cancer Res 22:821-6|
|Jacobus, S J; Rajkumar, S V; Weiss, M et al. (2016) Randomized phase III trial of consolidation therapy with bortezomib-lenalidomide-Dexamethasone (VRd) vs bortezomib-dexamethasone (Vd) for patients with multiple myeloma who have completed a dexamethasone based induction regimen. Blood Cancer J 6:e448|
|Barta, Stefan K; Li, Hailun; Hochster, Howard S et al. (2016) Randomized phase 3 study in low-grade lymphoma comparing maintenance anti-CD20 antibody with observation after induction therapy: A trial of the ECOG-ACRIN Cancer Research Group (E1496). Cancer 122:2996-3004|
|Moots, Paul L; O'Neill, Anne; Londer, Harold et al. (2016) Preradiation Chemotherapy for Adult High-risk Medulloblastoma: A Trial of the ECOG-ACRIN Cancer Research Group (E4397). Am J Clin Oncol :|
|Haas, Naomi B; Manola, Judith; Uzzo, Robert G et al. (2016) Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet 387:2008-16|
|Zent, Clive S; Victoria Wang, Xin; Ketterling, Rhett P et al. (2016) A phase II randomized trial comparing standard and low dose rituximab combined with alemtuzumab as initial treatment of progressive chronic lymphocytic leukemia in older patients: a trial of the ECOG-ACRIN cancer research group (E1908). Am J Hematol 91:308-12|
Showing the most recent 10 out of 30 publications